Polaryx Therapeutics, Inc.
PLYX
$2.28
-$0.18-7.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 264.39% | -23.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 114.93% | -6.47% | |||
| Operating Income | -114.93% | 6.47% | |||
| Income Before Tax | -70.17% | -4.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -70.17% | -4.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.17% | -4.55% | |||
| EBIT | -114.93% | 6.47% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -68.97% | -2.24% | |||
| Normalized Basic EPS | -69.35% | -2.05% | |||
| EPS Diluted | -68.97% | -2.24% | |||
| Normalized Diluted EPS | -69.35% | -2.05% | |||
| Average Basic Shares Outstanding | 0.74% | 2.36% | |||
| Average Diluted Shares Outstanding | 0.74% | 2.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||